The U.S. Food and Drug Administration approval provides a new treatment option for patients whose cancer is not responding to crizotinib The U.S. Food and Drug Administration (FDA) has approved the molecularly targeted therapeutic...
The FDA recently added another therapeutic to the armamentarium for oncologists treating certain patients with lung cancer: necitumumab.
The FDA expanded the use of the immune checkpoint inhibitor nivolumab to include certain patients with kidney cancer.
The FDA approved a new therapeutic, ixazomib, for treating certain patients with multiple myeloma. Learn about this FDA treatment approval.
The U.S. Food and Drug Administration (FDA) approved the immunotherapeutic elotuzumab (Empliciti) for treating certain patients with multiple myeloma.
Daratumumab is intended for patients whose multiple myeloma has worsened despite receiving at least three other treatments for their disease.
The FDA approved a combination of molecularly targeted therapies for treating certain patients with melanoma.
A first-of-its kind immunotherapeutic has been approved by the FDA for the treatment of melanoma lesions in the skin and lymph nodes.
The FDA has approved trabectedin for the treatment of certain patients with two types of soft tissue sarcoma, liposarcoma and leiomyosarcoma.
A nanotherapeutic form of the conventional chemotherapeutic has been approved by the FDA for treating certain patients with pancreatic cancer.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now